V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 290005659 | 290004094 | 1.82 | 103 | Curative (C) | 2015-08-14 | 2015-08-22 | Capecitabine | 02 | N | 290026118 | CETUXIMAB + RT |
| 290005660 | 290004095 | 1.69 | 61 | Palliative (P) | 2019-03-16 | 2019-03-30 | CARBOPLATIN + ETOPOSIDE | N | N | 290026179 | CARBOPLATIN |
| 290005661 | 290004095 | 1.51 | 61 | Neo-adjuvant (N) | 2016-04-04 | 2016-04-18 | LANREOTIDE | N | Y | 290026179 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 290005662 | 290004096 | null | 68.4 | Palliative (P) | 2016-11-06 | 2016-11-06 | DABRAFENIB | N | N | 290026203 | CARBOPLATIN + CETUXIMAB + FU |
| 290005663 | 290006731 | 1.68 | null | Adjuvant (A) | 2018-12-29 | 2018-12-29 | Cyclophosphamide + Docetaxel | 02 | null | 290026213 | OCTREOTIDE |
| 290005664 | 290004097 | 1.73 | null | null | 2018-03-25 | 2018-03-25 | OCTREOTIDE | null | N | 290026225 | IPILIMUMAB |
| 290005665 | 290004098 | 1.78 | 53.2 | Adjuvant (A) | 2014-08-08 | 2014-08-11 | EOX | 02 | N | 290026259 | INTERFERON |
| 290005666 | 290004098 | 1.66 | 61.8 | Neo-adjuvant (N) | 2016-11-18 | 2016-11-29 | Carboplatin + Pemetrexed | 02 | N | 290026259 | CARBOPLATIN + RT |
| 290005667 | 290004099 | 1.8 | 64.4 | Palliative (P) | 2017-01-04 | 2017-01-17 | Bortezomib + CYCLOPHOSPHAMIDE | N | N | 290026313 | CISPLATIN + FLUOROURACIL |
| 290005668 | 290004100 | 1.49 | 57.8 | null | 2014-07-11 | 2014-09-06 | Pazopanib | N | N | 290026321 | CAPECITABINE + RT |
| 290005669 | 290004101 | null | 73.8 | Palliative (P) | 2018-01-28 | 2018-02-24 | Capecitabine | 02 | Y | 290026332 | LANREOTIDE |
| 290005670 | 290004102 | 1.52 | 40.3 | Adjuvant (A) | 2019-04-02 | 2019-05-04 | Capecitabine (14 days)+Carboplatin | N | Y | 290026431 | LANREOTIDE |
| 290005671 | 290004103 | 1.73 | 112.8 | Curative (C) | 2014-05-22 | 2014-06-02 | Capecitabine | 2 | Y | 290026443 | CAPECITABINE + CISPLATIN |
| 290005672 | 290004104 | 1.68 | null | Adjuvant (A) | 2017-04-21 | 2017-05-12 | LANREOTIDE | N | N | 290026465 | OCTREOTIDE |
| 290005673 | 290006733 | 1.92 | 44.8 | Palliative (P) | 2016-04-02 | 2016-04-12 | Cisplatin +Fluorouracil (3 wk) | N | N | 290026510 | CISPLATIN + FLUOROURACIL |
| 290005674 | 290006733 | null | 65.5 | null | 2017-05-03 | 2017-05-03 | CISPLATIN + VINORELBINE | N | null | 290026510 | CAPECITABINE + RT |
| 290005675 | 290004105 | 1.71 | null | null | 2019-01-15 | 2019-01-19 | Carboplatin + Etoposide iv&po | N | null | 290026613 | SUNITINIB |
| 290005676 | 290006734 | 1.68 | 40.3 | Neo-adjuvant (N) | 2016-07-22 | 2016-10-04 | CISPLATIN + DOCETAXEL + FLUOROURACIL | N | Y | 290026759 | DABRAFENIB + TRAMETINIB |
| 290005677 | 290006734 | 1.79 | null | Curative (C) | 2017-11-14 | 2017-11-14 | MITOMYCIN | null | Y | 290026759 | FLUOROURACIL |
| 290005678 | 290004106 | 1.72 | null | Palliative (P) | 2014-06-30 | 2016-08-24 | Irinotecan + Modified De Gramont | 02 | N | 290026821 | EOX |
| 290005679 | 290004107 | 1.6 | 86.8 | Palliative (P) | 2018-10-01 | 2018-10-02 | Dacarbazine | N | N | 290026832 | CISPLATIN + GEMCITABINE |
| 290005680 | 290006735 | 1.74 | 67.6 | Palliative (P) | 2015-09-26 | 2015-10-13 | FLUOROURACIL + FOLINIC ACID | N | N | 290026848 | GEMCITABINE |
| 290005681 | 290004108 | null | null | Adjuvant (A) | 2018-01-21 | 2018-01-23 | CHOP R - 21 days | 2 | N | 290026867 | PLATO TRIAL |
| 290005682 | 290004109 | 1.66 | 37.8 | Adjuvant (A) | 2018-02-23 | 2018-02-23 | CAPECITABINE + RT | N | N | 290026954 | CISPLATIN + FLUOROURACIL |
| 290005683 | 290004110 | 1.63 | 107.7 | Palliative (P) | 2014-10-16 | 2014-10-26 | Gemcitabine + Capecitabine | 02 | N | 290026975 | LANREOTIDE |
| 290005684 | 290004110 | 1.62 | 85 | Palliative (P) | 2014-12-30 | 2015-01-04 | Etoposide oral | 02 | N | 290026975 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 290005685 | 290004111 | 1.65 | 50 | Curative (C) | null | 2016-06-12 | PLATO Trials | N | Y | 290027026 | FLUOROURACIL |
| 290005686 | 290004112 | null | null | Palliative (P) | 2015-07-02 | 2015-07-16 | Carboplatin + Etoposide IV 3 day | N | N | 290027056 | EOX |
| 290005687 | 290004112 | 1.63 | null | null | 2013-07-25 | 2013-08-10 | Capecitabine | null | null | 290027056 | MITOMYCIN INTRAVESICULAR |
| 290005688 | 290004113 | 1.72 | 74 | Palliative (P) | 2014-03-13 | 2014-03-26 | Cisplatin + Etoposide po&iv 3 day | N | N | 290027146 | FLUOROURACIL |
| 290005689 | 290004114 | 1.74 | 68.5 | Not known (9) | null | 2013-08-09 | Fluorouracil 96hr infusion+R(4g/m2) | N | Y | 290027159 | RITUXIMAB |
| 290005690 | 290006738 | 1.71 | 73.6 | Palliative (P) | 2015-05-26 | 2015-05-26 | Cisplatin + Fluorouracil + RT 5day | 2 | N | 290027215 | LANREOTIDE |
| 290005691 | 290006738 | 1.8 | 83.2 | Palliative (P) | 2018-03-26 | 2018-03-30 | Carboplatin + Etoposide iv&po | 01 | N | 290027215 | CAPECITABINE + CISPLATIN |
| 290005692 | 290008217 | 1.58 | 68.8 | Curative (C) | 2016-02-21 | 2016-02-24 | LANREOTIDE | N | N | 290027323 | MCX |
| 290005693 | 290008217 | 1.63 | 58.9 | Palliative (P) | 2014-06-19 | 2014-07-10 | PLATO Trials | 02 | N | 290027323 | LANREOTIDE |
| 290005694 | 290004115 | 1.76 | 0 | Adjuvant (A) | null | 2019-04-25 | Docetaxel 75mg/m2 (21 day) | N | N | 290027389 | CAPECITABINE |
| 290005695 | 290004116 | 1.68 | 56 | Adjuvant (A) | 2017-06-07 | 2017-06-08 | LANREOTIDE | 02 | N | 290027409 | TRIAL |
| 290005696 | 290004116 | null | 57.2 | Curative (C) | null | 2015-06-28 | Pemetrexed | N | Y | 290027409 | FCARBOST |
| 290005697 | 290004117 | 1.72 | 84.5 | Palliative (P) | 2018-06-18 | 2018-07-12 | Cisplatin +Fluorouracil (3 wk) | Y | N | 290027471 | EOX |
| 290005698 | 290004117 | 1.68 | 82.1 | Palliative (P) | 2017-07-22 | 2017-07-27 | CISPLATIN + DOCETAXEL + FLUOROURACIL | 02 | N | 290027471 | LANREOTIDE |
| 290005699 | 290004118 | 1.62 | 69.1 | Palliative (P) | 2017-05-12 | 2017-05-12 | CISPLATIN + FLUOROURACIL | N | N | 290027501 | LANREOTIDE |
| 290005700 | 290004119 | 1.81 | 65.3 | Curative (C) | null | 2015-01-30 | PLATO Trials | N | N | 290027502 | DOCETAXEL |
| 290005701 | 290004120 | 0 | 88.5 | Neo-adjuvant (N) | 2017-10-20 | 2017-10-24 | Cisplatin +Fluorouracil (3 wk) | N | N | 290027629 | BEVACIZUMAB + OXALIPLATIN + MdG |
| 290005702 | 290004121 | null | 65.1 | Palliative (P) | 2016-02-26 | 2016-03-07 | Irinotecan + Modified De Gramont | N | N | 290027678 | CISPLATIN + FLUOROURACIL |
| 290005703 | 290004121 | null | 96 | Palliative (P) | 2014-04-10 | 2014-04-29 | FLUOROURACIL | N | N | 290027678 | CARBOPLATIN + ETOPOSIDE |
| 290005704 | 290004122 | 1.8 | 117 | Not known (9) | 2016-05-02 | 2016-05-21 | Capecitabine + Cisplatin | N | N | 290027758 | BORTEZOMIB + THALIDOMIDE |
| 290005705 | 290004122 | null | 60.9 | Palliative (P) | 2018-07-03 | 2018-07-17 | CISPLATIN + FLUOROURACIL | N | N | 290027758 | CISPLATIN + FLUOROURACIL |
| 290005706 | 290007830 | 1.68 | 86.3 | Curative (C) | 2016-03-26 | 2016-04-09 | Cisplatin + Etoposide po&iv 3 day | N | N | 290027933 | CETUXIMAB |
| 290005707 | 290004123 | 0 | 91.1 | Neo-adjuvant (N) | null | 2017-08-26 | LANREOTIDE | N | Y | 290027964 | CISPLATIN + ETOPOSIDE |
| 290005708 | 290004124 | 1.6 | 53.5 | Adjuvant (A) | 2017-02-07 | 2017-02-14 | Sunitinib | N | N | 290027970 | CISPLATIN + ETOPOSIDE |